8-K: Monogram Technologies Details Zimmer Biomet Acquisition Terms and CVRs in Shareholder FAQ

Monogram Technologies Inc. has issued a comprehensive FAQ to its stockholders, clarifying the terms of its proposed acquisition by Zimmer Biomet Holdings, Inc., including the cash consideration and contingent value rights.

Summary

• Monogram Technologies Inc. will be acquired by Zimmer Biomet Holdings, Inc., as previously announced on July 14, 2025.
• Upon consummation of the transaction, each outstanding Monogram common share will be converted into the right to receive $4.04 in cash and one Contingent Value Right (CVR).
• The merger is expected to close in the second half of 2025, pending regulatory and Monogram stockholder approval.
• CVRs are contractual rights to additional future cash payments, contingent upon the achievement of specific commercial, regulatory, or revenue-based milestones.
• CVRs are not tradeable or transferable (except under very limited conditions) and do not carry voting or dividend rights, nor do they represent equity or ownership interest.
• Potential CVR payments range from $1.04 up to $3.43 per CVR, but there is no guarantee these milestones will be met or that payments will occur.
• Monogram shares will continue trading on Nasdaq until the merger closes, after which Monogram will be delisted and become a wholly-owned subsidiary of Zimmer Biomet.
• Stockholders will receive a proxy statement with voting instructions in approximately 1-2 months to approve the proposed transaction.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive for Monogram shareholders, as the acquisition provides a clear cash exit and potential upside through CVRs. However, the non-guaranteed nature and illiquidity of the CVRs introduce a degree of uncertainty, preventing a higher score.

Positives

• Provides a clear cash payout of $4.04 per share for Monogram stockholders.
• Offers potential additional upside through Contingent Value Rights (CVRs) ranging from $1.04 to $3.43 per CVR.
• The acquisition by Zimmer Biomet, a larger industry player, provides a defined exit strategy for Monogram shareholders.

Negatives

• CVR payments are not guaranteed and are entirely contingent on the achievement of specific milestones, introducing uncertainty regarding the full potential value.
• CVRs are not tradeable or transferable, limiting liquidity and the ability to monetize the contingent value before milestones are met.
• Monogram will be delisted from Nasdaq post-merger, ending its independent public trading.

Risks

• Risks related to the satisfaction of closing conditions, including failure to obtain necessary regulatory approvals or Monogram stockholder approval.
• Possibility of competing offers or acquisition proposals for Monogram.
• Occurrence of any event, change, or circumstances that could lead to the termination of the definitive transaction agreement, potentially requiring Monogram to pay a termination fee.
• Inability to realize the anticipated benefits of the proposed transaction, or realization not within the expected timeframe.
• Risks that the businesses will not be integrated successfully.
• Risks relating to changing demand for Zimmer Biomet's and Monogram's existing products.
• Risks relating to the achievement, in part or at all, of the revenue and other milestones necessary for the payment of any contingent value rights.
• Disruption from the proposed transaction making it more difficult to maintain business and operational relationships, including with customers, vendors, service providers, and employees.
• Proposed transaction diverting Zimmer Biomet's and/or Monogram's managements' attention from ongoing business operations.
• Negative effects of the announcement or consummation of the proposed transaction on the market price of Zimmer Biomet's and/or Monogram's common stock and on operating results.
• Significant transaction costs and unknown liabilities.
• Risk of litigation, including stockholder litigation, and/or regulatory actions, including any conditions, limitations, or restrictions placed on approvals by governmental entities related to the proposed transaction.

Future Outlook

The proposed acquisition by Zimmer Biomet is expected to close in the second half of 2025, subject to regulatory and Monogram stockholder approvals. Future payments to Monogram shareholders holding CVRs are contingent upon the combined company achieving specific commercial, regulatory, or revenue-based milestones, with no guarantee of payment.

Management Comments

• Monogram Technologies Inc. provided frequently asked questions (FAQs) to its stockholders to clarify details regarding the proposed acquisition by Zimmer Biomet Holdings, Inc.

Industry Context

This acquisition represents a strategic move by Zimmer Biomet, a global leader in musculoskeletal healthcare, to integrate Monogram Technologies. While the specific nature of Monogram's technology isn't detailed in this FAQ, such acquisitions typically aim to expand product portfolios, enhance technological capabilities (e.g., in robotics, personalized medicine, or advanced implants), or consolidate market share within the competitive medical technology and orthopedic sectors. This aligns with a broader industry trend of consolidation and innovation-driven M&A among medical device companies.

Comparison to Industry Standards

• NA

Legal Proceedings

• The filing notes a risk of litigation, including stockholder litigation, and/or regulatory actions related to the proposed transaction.

Stakeholder Impact

• Shareholders: Will receive $4.04 cash per share and one CVR, with potential for additional payments, but lose direct equity ownership in Monogram.
• Employees: May experience changes due to business integration with Zimmer Biomet, including potential shifts in roles or reporting structures.
• Customers, Vendors, Service Providers: Business and operational relationships may be disrupted during the integration process.

Next Steps

• Monogram will file relevant materials with the SEC, including preliminary and definitive proxy statements relating to the proposed transaction.
• The definitive proxy statement will be mailed to Monogram's stockholders in approximately 1-2 months, providing voting instructions.
• Monogram stockholders will need to vote on the proposed transaction.
• Zimmer Biomet and Monogram will work to obtain necessary regulatory approvals.
• The merger is expected to close in the second half of 2025.
• Upon closing, Monogram will be delisted from Nasdaq and become a wholly-owned subsidiary of Zimmer Biomet.

Key Dates

Recommendation

For existing Monogram Technologies shareholders, holding shares until the merger closes is recommended to receive the fixed cash consideration of $4.04 per share and the Contingent Value Right (CVR). While the CVR payments are not guaranteed and are illiquid, they offer potential additional upside. Selling before closing would forfeit the right to both the cash payout and the CVRs. New investors should assess the current market price relative to the $4.04 cash component plus the estimated value of the CVR, considering its inherent risks and illiquidity.

Keywords

Monogram Technologies, Zimmer Biomet, Acquisition, Merger, Contingent Value Right, CVR, Medical Technology, Orthopedics, SEC Filing, 8-K, Corporate Action